Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
https://www.zacks.com/commentary/2232353/top-analyst-reports-for-eli-lilly-procter-gamble-morgan-stanley?cid=CS-ZC-FT-research_daily-2232353
Feb 27, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
0
Eli Lilly: Overvaluation Is A Big Red Flag
https://seekingalpha.com/article/4669991-eli-lilly-q4-earnings-overvaluation-big-red-flag?source=feed_all_articles
Feb 13, 2024 - Eli Lilly has strong financial performance with steady revenue growth and profitability expansion. Find out why LLY stock is a Sell.
0
Eli Lilly partner BioAge wins $170M to study Zepbound combo
https://seekingalpha.com/news/4066258-eli-lilly-partner-bioage-wins-170m-zepbound-combo-study?source=feed_sector_healthcare
Feb 13, 2024 - Biotech startup BioAge Labs raises $170M for Phase 2 trials for a combination therapy involving Eli Lilly's Zepbound and other weight loss drugs. Read more here.
0
Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?
https://www.fool.com/investing/2024/02/10/eli-lilly-just-succeeded-where-others-failed-but-d/?source=iedfolrf0000001
Feb 10, 2024 - Potentially adding billions of dollars in revenue might move the needle for the pharmaceutical giant, but that could take years.
0
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
https://www.cnbc.com/2024/02/10/weight-loss-drugs-novo-nordisk-eli-lilly-are-tackling-supply-issues.html
Feb 10, 2024 - Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
0
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/?source=iedfolrf0000001
Feb 08, 2024 - Investors are still excited about obesity treatments and weight-management drugs.
0
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
https://www.zacks.com/stock/news/2222669/etfs-to-buy-as-mounjaro-powers-eli-lilly-s-q4-earnings-beat?cid=CS-ZC-FT-etf_news_and_commentary-2222669
Feb 07, 2024 - Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
0
Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes
https://www.cnbc.com/2024/02/06/healthy-returns-novo-nordisk-eli-lilly-tackle-weight-loss-drug-supply-woes.html
Feb 06, 2024 - Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
0
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
https://www.cnbc.com/2024/02/06/eli-lilly-weight-loss-drug-may-treat-fatty-liver-disease.html
Feb 06, 2024 - The results add to a long list of potential health benefits of tirzepatide besides helping patients shed significant pounds and regulate blood sugar.
0
Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy
https://seekingalpha.com/news/4063338-nash-drug-developers-drop-trial-win-lilly-drug?source=feed_sector_healthcare
Feb 06, 2024 - Companies focused on NASH drugs drop as Eli Lilly's (LLY) weight loss drug, tirzepatide, hits main goal in a mid-stage trial for the liver disease. Read more here.
0